CAJ | 학술논문

抗凝治疗是急性冠状动脉综合征、心房颤动、静脉血栓形成、肺栓塞等栓塞类疾病非常有效的治疗手段。抗凝药物包括肝素、华法林、达比加群、利伐沙班、阿哌沙班等。抗凝药物剂量个体差异大、出血风险高。如何提高抗凝治疗的有效性和安全性作为目前的研究热点。基因多态性在抗凝药物的剂量效应关系方面起了非常重要的作用。本文旨在探讨影响华法林、达比加群等抗凝药物的遗传因素，为个体化治疗提供依据。
항응치료시급성관상동맥종합정、심방전동、정맥혈전형성、폐전새등전새류질병비상유효적치료수단。항응약물포괄간소、화법림、체비가군、리벌사반、아고사반등。항응약물제량개체차이대、출혈풍험고。여하제고항응치료적유효성화안전성작위목전적연구열점。기인다태성재항응약물적제량효응관계방면기료비상중요적작용。본문지재탐토영향화법림、체비가군등항응약물적유전인소，위개체화치료제공의거。
Anticoagulation therapy is currently prescribed for treatment on thrombotic disorders, such as acute coronary syndromes, atrial fibrillation, vein thrombosis, pulmonary embolism. Currently, anticoagulants include heparin, warfarin, dabigatran, rivaroxaban, apixaban and so on. However, anticoagulants vary in dose on individual patient. One of the hot researches is how to increase the efifcacy and safety of anticoagulation. Genetic polymorphisms are thought to contribute to the wide intraindividual variability in anticoagulant drug response. Here, we review the genetic mechanisms contributing to the variability in response to warfarin and dabigatran, and propose the personal management of anticoagulation therapy.